Letrozole Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 2.5 mg
Reference Brands: Femara® (US & EU)
Category: Oncology Cancer Care
Letrozole is available in Tablets and strengths such as 2.5 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Letrozole is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Letrozole can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Product Description: Letrozole, sold under the brand name Femara®, is a highly effective aromatase inhibitor used in the treatment of hormone receptor-positive breast cancer in postmenopausal women. Approved in both the US and EU, Letrozole is available in 2.5 mg oral tablets and is widely prescribed for early and advanced-stage breast cancer. As a key hormonal therapy, Letrozole is sourced globally by B2B pharmaceutical wholesalers, hospitals, and oncology clinics. With GMP-compliant manufacturing and reliable supply chains, Letrozole offers consistent quality and competitive pricing in the European and American markets, supporting cancer care with trusted pharmaceutical standards.
Frequently Asked Questions
Related Products
Atezolizumab
Strength: 1200 mg/20 mL
Form: Intravenous infusion
Reference Brands: Tecentriq® (EU & US)
View Details
Durvalumab
Strength: 120 mg/4 mL, 500 mg/10 mL
Form: Injection
Reference Brands: Imfinzi® (US & EU)
View Details
Sunitinib
Strength: 12.5 mg, 25 mg, 37.5 mg, 50 mg
Form: Tablet
Reference Brands: Sutent® (EU & US)
View DetailsQuick Response Guaranteed | Verified Suppliers